OBJECTIVE: To determine whether interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-2, IL-4, interferon-gamma (IFN gamma), IL-6, and tumor necrosis factor alpha (TNF alpha) are detected more frequently in sera from scleroderma patients than in sera from controls. METHODS: Serum concentrations of these cytokines were measured in 78 scleroderma patients and 73 controls, using enzyme-linked immunosorbent assay, radioimmunoassay, and bioassay techniques. RESULTS: IL-2, IL-4, and IL-6 were each detected more frequently in sera from scleroderma patients than in sera from controls. TNF alpha and IL-1 alpha were found with equal frequency in patient and control sera. IL-1 beta and IFN gamma were not detected in any sera. CONCLUSION: IL-2, IL-4, and IL-6 may be among the cytokines that contribute to the disease process in scleroderma patients. To our knowledge, this is the first report of elevated serum IL-4 levels in human disease.
OBJECTIVE: To determine whether interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-2, IL-4, interferon-gamma (IFN gamma), IL-6, and tumor necrosis factor alpha (TNF alpha) are detected more frequently in sera from sclerodermapatients than in sera from controls. METHODS: Serum concentrations of these cytokines were measured in 78 sclerodermapatients and 73 controls, using enzyme-linked immunosorbent assay, radioimmunoassay, and bioassay techniques. RESULTS:IL-2, IL-4, and IL-6 were each detected more frequently in sera from sclerodermapatients than in sera from controls. TNF alpha and IL-1 alpha were found with equal frequency in patient and control sera. IL-1 beta and IFN gamma were not detected in any sera. CONCLUSION:IL-2, IL-4, and IL-6 may be among the cytokines that contribute to the disease process in sclerodermapatients. To our knowledge, this is the first report of elevated serum IL-4 levels in human disease.
Authors: R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti Journal: Clin Exp Immunol Date: 2001-08 Impact factor: 4.330
Authors: G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati Journal: J Clin Immunol Date: 2001-05 Impact factor: 8.317
Authors: S Veeraraghavan; E A Renzoni; H Jeal; M Jones; J Hammer; A U Wells; C M Black; K I Welsh; R M du Bois Journal: Ann Rheum Dis Date: 2004-08 Impact factor: 19.103